Brooklyn, New York, Aug. 04, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Biopharmaceutical Stability Testing Market is projected to grow from USD 3.2 billion in 2022 to USD 10.8 billion in 2027 at a CAGR of 13.3% from 2022 to 2027.
The major driver in the biopharmaceutical stability testing market is the increase in disposable income of developing countries. Many consumers are relying on homegrown fruits and vegetables. This increases demand for greenhouses vertical and indoor farms. Also, horticulture lighting is energy efficient and the energy consumption is less than regular farming.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on “Global Biopharmaceutical Stability Testing Market - Forecast to 2027’’
Key Market Insights
- As per the type outlook, the monoclonal antibodies & antibody-drug conjugates segment is expected to be the largest segment in the biopharmaceutical stability testing market from 2022 to 2027
- The Asia Pacific region is analyzed to be the fastest-growing segment in the market
- United States has the largest share in the market during the forecast period of 2022-2027.
- As per the end-user, the pharmaceutical & biopharmaceutical companies segment is expected to be the largest segment in the biopharmaceutical stability testing market from 2022 to 2027
- Intertek Group plc, Eurofins Scientific, Pacific Biolabs, SGS SA, Element Materials Technology, Almac Group, Merck KGaA, Catalent, Inc., Pace Analytical Life Sciences, Boston Analytical, Kemwell Biopharma, Curia Global, Inc., Thermo Fisher Scientific, Inc., ProtaGene, Alcami Corporation, Inc., Symmetric s.r.o., LGM Pharma, and LabCorp, among others, are key players in the biopharmaceutical stability testing market.
Request a Sample Copy of the Report @ https://www.globalmarketestimates.com/market-report/biopharmaceutical-stability-testing-market-3889
Type Outlook (Revenue, USD Billion, 2022-2027)
- Monoclonal Antibodies & Antibody-Drug Conjugates
- Recombinant Proteins
- Vaccines
- Others
End-User Type Outlook (Revenue, USD Billion, 2022-2027)
- Pharmaceutical & Biopharmaceutical Companies
- CMOs & CROs
- Academic & Government Research Institutes
Regional Outlook (Revenue, USD Billion, 2022-2027)
North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Thailand
- Indonesia
- Malaysia
- Singapore
- Vietnam
- Rest of APAC
Central & South America
- Brazil
- Argentina
- Chile
- Rest of CSA
Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of MEA
Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +1 6026667238
